Elixir Associates

🚀! Big News from Monopar Therapeutics Inc. ! 🚀 In an exciting development, Monopar received clearance to start their Phase 1 trial for MNPR-101-Lu in advanced cancers! 🔹 What's MNPR-101-Lu? ☢️A novel radiopharmaceutical combining lutetium-177 with a proprietary MNPR-101 antibody. ☢️Targets aggressive cancers like triple-negative breast and pancreatic cancer. 🔹 Why It Matters: ☢️Preclinical studies showed durable antitumor effects after just one dose! ☢️This trial aims to deliver meaningful benefits for patients battling tough-to-treat cancers. #CancerResearch #Radiopharma #Innovation #MonoparTherapeutics #radiotherapeutics #radioisotopes

Exciting News in Kidney Disease Research 🌟 Today marks a significant step forward in the fight against kidney disease. Borealis Biosciences, a new biotech company launched by Novartis and Versant Ventures, has emerged from stealth mode with a remarkable $150 million in Series A funding. This venture builds upon the successful acquisition of Chinook Therapeutics by Novartis, showcasing a continued commitment to innovative renal therapies. Borealis boasts a talented team of 25, many of whom are key figures from Chinook's Vancouver-based research team. Their mission? To develop next-generation RNA medicines for kidney disease, utilizing recent advancements in patient stratification, genetically defined targets, and RNA chemistry. Alongside the Series A funds, Borealis has secured an additional $100 million from a licensing deal with Novartis, highlighting the Big Pharma's dedication to renal medicine and xRNA technology. Versant and Novartis aim to foster an environment that drives pioneering renal science and drug discovery. Given the progress Borealis is set to achieve, it's clear that the journey to groundbreaking kidney disease treatments is just beginning. #KidneyDisease #Biotech #RNA #Pharma #Innovation

“Choose a job you love, and you will never have to work a day in your life.” - My dream growing up was to be a ''Sports Presenter'' as I've always been a sports geek but sometimes your dreams change & you end up doing something else which elevates you as a person & makes you happy. 👣 I wake up every morning & never think ''I've got work today'' or ''It's going to be a long day today''.... these thoughts never cross my mind. ⛔ I wake up every morning... I feel blessed knowing I love what I do so don't really see it as a job. I get to travel the world, meeting some incredible people across the globe who are working tirelessly to help saves millions of lives. I get the chance to deal with & solve problems on a daily basis. I get to have some great laughs & banter with every single individual at Elixir Associates. I get to see some amazing clients happy with the perfect candidates that we find them. I get the chance to learn from mistakes that I make every day. I take risks everyday... I wouldn't change a single thing... so grateful to be doing something I love & enjoy. 🧡 Starting Elixir Associates at the start of 2023 was a very tough decision during a year of uncertainty in the Biotech, CRO & Pharma industry. It was a tough year & I had so many nights where going to sleep was difficult as I was anxious... did I make the right decision... what if it doesn't work out... I can't let anyone down... you start to doubt yourself... you think what is my Plan B if it doesn't work out.. what is my fall back plan. You know what got me through the tough period.... knowing how much I enjoy what I do & the people who joined Elixir and trusted the process from day 1. Every single one of them will always have a special place in my heart forever... they are like family to me. 🤟 If you are reading this, always chase your dreams, take risks & find your dream job... don't just settle for anything. Don't ever let someone tell you that you can't do something. In this day & age, people can't do something themselves so they will tell you you can't do it. You have a dream, work hard & I promise you it will happen. There are no shortcuts & along the way you will fail and fall badly but you just have to keep getting up & keep trying. If you don't fail, you are not even trying. #Elixir #Dreams #Hardwork #StartUpBusiness #Staffing

🧠 Mental Health & Lupus: Unveiling a Vital Link 🌍 It is well-known that a Lupus diagnosis often leads to mental health challenges. But what if the reverse is also true? 🤔 Recent research has highlighted the significant association between mental health conditions (MHCs) and the development of Systemic Lupus Erythematosus (SLE). A comprehensive meta-analysis of over 1.48 million individuals reveals: 📊High prevalence of MHCs: 59.7% of adults with SLE suffer from sleep disturbances, while 63.4% of children face cognitive dysfunction. 📊Increased SLE risk: Depression (2.3x) and PTSD (1.9x) significantly raise the likelihood of developing SLE. 📊Impact on outcomes: MHCs lead to a lower quality of life and a greater risk of additional health issues. These findings underscore the need for holistic care that addresses both mental and physical health in SLE patients. They tell us more about the impacts of (neuro)inflammation across multiple health domains and diseases #MentalHealth #Lupus #AutoimmuneDisease #ChronicIllness #Healthcare #Rheumatology

After a Record Breaking Q2, the team at Elixir Associates had a lovely day out last Friday to celebrate in style.🎉 The food at Dishoom (highly recommend if you have never been) was just incredible & by the time this picture was taken, I think everyone was super stuffed.🥘👌 I’m so proud of every single person for all their hard works so far in 2024. ♥️ The upcoming months are going to be incredible … watch this space 🙌🏽 #Celebrating #Proud #Elixir #Staffing #Dishoom #Biotech #Pharma

Incyte has just unveiled some promising results as their pivotal Phase 3 trial, inMIND, has shown that tafasitamab, when combined with lenalidomide and rituximab, effectively treats relapsed or refractory follicular lymphoma (FL). The trial not only met its primary endpoint of progression-free survival (PFS) but also achieved crucial secondary endpoints 📊 Follicular lymphoma is the most common indolent B-cell non-Hodgkin lymphoma and significantly affects many patients in the UK. Tafasitamab, a monoclonal antibody targeting CD19, showed no new safety concerns when used alongside the standard care. With these positive results, Incyte is planning to file a supplemental license application for tafasitamab in FL by the end of the year. This move could potentially bring a revolutionary treatment to a broader patient base ✅ #Incyte #OncologyResearch #CancerTreatment #Biotech #Lymphoma #ClinicalTrials #ClinicalResearch #LifeScience #ElixirAssociates #StaffingPartner

🚀 Exciting News in MedTech! 🚀 Today, Neptune Medical announced a significant milestone: raising $97 million in venture capital and launching its new subsidiary, Jupiter Endovascular. 🌟 Jupiter Endovascular is aimed at revolutionising catheter-based therapies, initially focussing on treating blood clots in the lung. With $21 million in funding, they plan to begin clinical trials for their Endoportal Control technology. This innovative hardware maintains flexibility in blood vessels, turning rigid when needed for precise pulmonary embolism procedures. This brings surgical precision to minimally invasive methods, addressing a critical clinical need. 👩⚕️👨⚕️ Neptune Medical's commitment to pushing the boundaries of GI robotics continues alongside Jupiter's endovascular innovations. "These milestones allow us to sharpen our focus on GI robotics while empowering Jupiter to drive innovation in endovascular treatments," said founder and CEO Alex Tilson. With dedicated resources, both companies are set to lead in their respective fields, delivering transformative solutions to patients worldwide. 🌐 #MedicalTechnology #HealthcareInnovation #ClinicalResearch #JupiterEndovascular #NeptuneMedical

Genentech going through a major shift. Famous cell biologist Ira Mellman is leaving after 17 great years, causing the cancer immunology research department to close. This part will join with the molecular oncology team to create a combined cancer research group in Genentech Research and Early Development (gRED). Mellman's big contributions to cancer immunology, like his important work on endosomes and new cancer treatments, have made a lasting impact. His exit marks the end of an important era. Genentech says this restructure is a smart move to take advantage of new scientific opportunities, and it doesn't mean they're less committed to cancer immunology. The company is still focused on blending immunotherapy with their larger cancer research efforts. These changes come at a tough time for Genentech's cancer immunotherapy projects, with challenges in the anti-TIGIT program and shifts in other priorities. #CancerResearch #Biotechnology #LifeSciences

🚀 Great news for patients as the US FDA has given the green light to Gilead Sciences Livdelzi (seladelpar) for treating primary biliary cholangitis (PBC), a chronic autoimmune disease that mainly affects women. PBC impacts the bile ducts and, if left untreated, can lead to severe liver damage. Livdelzi's approval not only brings newfound hope for patients but also underscores the importance of continuous innovation in the medical field. In a Phase 3 study, Livdelzi made impressive strides: - ✅ Achieved a significant biochemical response in 62% of participants (compared to 20% with placebo) - ✅ Normalised alkaline phosphatase (ALP) levels in 25% of participants - ✅ Reduced pruritus (itching) significantly These achievements are particularly pivotal given that current treatment options often fall short, failing to prevent liver damage over the long term. While the long-term benefits in terms of survival and liver damage prevention remain to be seen, Livdelzi's ability to normalise ALP levels, a key marker for predicting transplant risk and mortality, positions it as a game-changer in PBC management. #GileadSciences #Livdelzi #Biotechnology #Pharmaceuticals #HealthcareInnovation #ClinialTrials #ClinicalResearch #LifeScience #ElixirAssociates #StaffingPartner

Below are some exciting new EXECUTIVE appointments which have taken place recently over the last week. 👨🔬 👩🔬 ➖ Cerevance have appointed Sagar Vaidya as their new CMO.✅ ➖ Oculis have appointed Sharon Klier as their new CDO.✅ ➖ Xenon Pharmaceuticals Inc. have appointed Matthew Ronsheim as their new COO.✅ ➖ Cellphire Therapeutics, Inc. Therapeutics have appointed Damien Bates MD, PhD, FRACS, MBA as their new CMO.✅ ➖ axogen have appointed Michael Dale as their new CEO.✅ ➖ Cellectis have appointed Dr. Adrian Kilcoyne MD MPH MBA as their new CMO.✅ ➖ 89bio have appointed Francis Sarena as their new COO.✅ ➖ Ovid Therapeutics have appointed Amanda Banks, MD as their new CDO.✅ ➖ Cyclerion have appointed Regina Graul as their new CEO.✅ Huge congratulations to all these incredible leaders from myself & everyone at Elixir Associates. 👏 👏 👏 #Appointments #Leaders #Executive #Congratulations #News #Elixir #Leadership #Hiring #Regulatory #Clinical #DrugDevelopment #Medical #LifeSceinces #Healthcare #Pharma #Biotech #Staffing #Recruitment #Therapeutics